KRINTAFEL (tafenoquine)

KRINTAFEL (tafenoquine)

SELF-ADMINISTRATION - ORAL

Indication for Prior Authorization:

• Indicated for patients ≥ 16 years of age for the radical cure (prevention of relapse) of Plasmodium vivax malaria who are receiving appropriate antimalarial therapy for acute P. vivax infection.
• Not indicated for the treatment of acute P. vivax malaria.

Patients must meet the following criteria for the indication(s) above:

• Patient is 16 years of age or older, AND
• Diagnosis of Plasmodium vivax malaria, AND
• Prescribed by or in consultation with an infectious disease specialist, AND
• Prescribed in combination with an appropriate antimalarial therapy (e.g. chloroquine) for acute P. vivax infection, AND
• Does not exceed dose of 300 mg (two-150 mg tablets) as a single dose
• Contraindication:
  • G6PD deficiency or unknown G6PD status

Dosing:

• Oral: 300 mg as a single dose on the first or second day of the appropriate antimalarial therapy
• Dose does not exceed 300 mg (two-150 mg tablets) as a single dose

Approval:

• 1 treatment (2 tablets only)